LUND, Sweden – Cellevate AB, an innovative biotech company that develops the next generation of cell culture systems designed to revolutionize biomanufacturing, today announces that Associate Professor, Dr. Véronique Chotteau, has been appointed to the company’s Scientific Advisory Board. Dr. Chotteau is the Principal Investigator of the Cell Technology group at KTH (The Royal Institute of Technology), Stockholm and Director of VINNOVA Competence Centre for Advanced BioProduction by Continuous Processing, AdBIOPRO.
Dr. Véronique Chotteau has more than 30 years of experience in mammalian cell culture including more than 10 years in biopharmaceutical industry (at Pharmacia Upjohn/Biovitrum, Stockholm, nowadays Swedish Orphan Biovitrum). She joined KTH in 2008, when she was offered to lead the animal cell cultivation activities, due to her expertise in cell culture and her industrial background. Her group is world-leader in high cell density perfusion of mammalian cell-based processes for biopharmaceutical production and is highly active in mathematical modeling of culture process, as well as in human stem cell bioprocessing.
“It is always exciting to work with new technology which can enable novel avenues or alleviate bottlenecks. With the increasing need for ATMP’s (Advanced Therapy Medicinal Products) commercialization, our field needs to create better or alternative ways for the culture of adherent cells. Cellevate has developed an interesting new type of microcarriers, that can make a difference”, says Dr. Véronique Chotteau.
“Dr. Chotteau’s wealth of experience and knowledge is not only covering the field of mammalian cell culture in biopharmaceutical industry but also continuous bioprocessing in large scale biologics production. We are therefore delighted that she has agreed to join our Scientific Advisory Board”, says Laura Chirica, CEO Cellevate.
For more information, please contact:
Laura Chirica, PhD
Cellevate is a spin out from NanoLund - a world leading nanomaterial academical center. The company founded in 2014, develops and markets products based on a proprietary nanofiber-based platform - the Cellevat3d™ - a game-changing, green and sustainable, deep-tech innovation for the biopharmaceutical industry. This platform allows for an industrial-scale production of microcarriers with unparalleled surface area for cell growth, reproducibility and customization. Cellevat3d™ microcarriers products are designed for laboratory testing of cell lines as well as pilot and large-scale batch production of novel classes of biological therapies, including cell- and gene therapies and vaccines. Cellevat3d™ microcarriers have a commercial launch and sales start planned for 2024.
For more information, please visit www.cellevate.com.